PerkinElmer announced it has entered into an agreement to acquire BioLegend, a global provider of life science antibodies and reagents, for approximately $5.25 billion in a combination of cash and stock.
BioLegend provides its academic and biopharmaceutical customers with antibodies and reagents in areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing.
PerkinElmer said the transaction will be the largest in the company’s history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary closing conditions.
Privately held BioLegend has more than 700 employees based primarily in the U.S.
